Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: Synagis TM
Active ingredients: palivizumab
What it is used for
Synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of prematurity (gestational age less than or equal to 35 weeks at birth) and children with haemodynamically significant congenital heart disease (CHD). (See Clinical Trials).
How to take it
The way to take this medicine is: Intramuscular. This medicine is given through a needle inserted into the muscle beneath the skin.
- Store at 2 to 8 degrees Celsius
- Store in Original Container
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Clear or slightly opalescent, sterile solution.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Need more information?
These trusted information partners have more on this topic.
Top results
Bronchiolitis - MyDr.com.au
Bronchiolitis is a viral chest infection that affects mainly babies under a year old and may cause breathing difficulties, wheeze and a cough.
Read more on myDr website
Respiratory syncytial virus (RSV): Frequently asked questions (FAQs) | NCIRS
Read more on National Centre for Immunisation Research and Surveillance (NCIRS) website
Top results
